{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T17:35:28Z","timestamp":1747157728673,"version":"3.40.5"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Neurology and Neurosurgery"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.clineuro.2024.108552","type":"journal-article","created":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T06:48:49Z","timestamp":1726123729000},"page":"108552","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The patient-reported outcomes for the new brand-generic teriflunomide in relapsing-remitting multiple sclerosis"],"prefix":"10.1016","volume":"246","author":[{"given":"Roya","family":"Abolfazli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyed Massood","family":"Nabavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amirreza","family":"Azimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammadali","family":"Nahayati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kurosh","family":"Gharagozli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamidreza","family":"Torabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monireh","family":"Ghazaeian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahra","family":"Rezagholi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3593-1852","authenticated-orcid":false,"given":"Sara","family":"Samadzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.clineuro.2024.108552_bib1","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.3892\/etm.2017.4410","article-title":"Multiple sclerosis: pathology, diagnosis and treatments","volume":"13","author":"Huang","year":"2017","journal-title":"Exp. Ther. Med"},{"issue":"14","key":"10.1016\/j.clineuro.2024.108552_bib2","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition","volume":"26","author":"Walton","year":"2020","journal-title":"Mult. Scler."},{"issue":"12","key":"10.1016\/j.clineuro.2024.108552_bib3","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1007\/s00415-019-09395-w","article-title":"Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis","volume":"267","author":"Li","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.clineuro.2024.108552_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102521","article-title":"An analysis of first-line disease-modifying therapies in patients with relapsing-remitting multiple sclerosis using the French nationwide health claims database from 2014-2017","volume":"46","author":"Vermersch","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"6","key":"10.1016\/j.clineuro.2024.108552_bib5","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s40265-014-0212-x","article-title":"Teriflunomide and its mechanism of action in multiple sclerosis","volume":"74","author":"Bar-Or","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.clineuro.2024.108552_bib6","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2147\/PROM.S156279","article-title":"The importance of patient-reported outcomes in clinical trials and strategies for future optimization","volume":"9","author":"Mercieca-Bebber","year":"2018","journal-title":"Patient Relat. Outcome Meas."},{"key":"10.1016\/j.clineuro.2024.108552_bib7","first-page":"61","article-title":"Patient-reported outcomes (PROs) and patient-reported outcome measures (PROMs)","volume":"6","author":"Weldring","year":"2013","journal-title":"Health Serv. Insights"},{"unstructured":"Berwick, D., Black, N., Cullen, D., Deerberg-Wittram, J., Degos, L., Diverty, B., Epstein, A., Kieny, M.-P., Larsen, B.-I., Schneider, E., Schreck, S., Sheingold, S., Wigzell, O., Recommendations to OECD ministers of health from the high level reflection group on the future of health statistics: strengthening the international comparison of health system performance through patient-reported indicators. 2017: Paris: OECD.","key":"10.1016\/j.clineuro.2024.108552_bib8"},{"issue":"4","key":"10.1016\/j.clineuro.2024.108552_bib9","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1177\/1756285616634247","article-title":"Therapy satisfaction and adherence in patients with relapsing-remitting multiple sclerosis: the THEPA-MS survey","volume":"9","author":"Haase","year":"2016","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.clineuro.2024.108552_bib10","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.msard.2018.09.017","article-title":"Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practice","volume":"26","author":"Coyle","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"10","key":"10.1016\/j.clineuro.2024.108552_bib11","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1212\/WNL.0000000000002441","article-title":"Long-term safety and efficacy of teriflunomide: nine-year follow-up of the randomized TEMSO study","volume":"86","author":"O'Connor","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.clineuro.2024.108552_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ensci.2022.100396","article-title":"Favorable benefit-risk ratio with teriflunomide treatment in relapsing-remitting multiple sclerosis: results of the 2-year, multicenter, prospective, noninterventional TAURUS MS study in Austria","volume":"27","author":"Guger","year":"2022","journal-title":"eNeurologicalSci"},{"key":"10.1016\/j.clineuro.2024.108552_bib13","doi-asserted-by":"crossref","DOI":"10.1177\/11795735211028781","article-title":"Efficacy and safety of teriflunomide in multiple sclerosis across age groups: analysis from pooled pivotal and real-world studies","volume":"13","author":"Oh","year":"2021","journal-title":"J. Cent. Nerv. Syst. Dis."},{"key":"10.1016\/j.clineuro.2024.108552_bib14","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.3389\/fimmu.2019.01564","article-title":"Immunological aspects of approved MS therapeutics","volume":"10","author":"Rommer","year":"2019","journal-title":"Front Immunol."},{"issue":"2","key":"10.1016\/j.clineuro.2024.108552_bib15","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"issue":"14","key":"10.1016\/j.clineuro.2024.108552_bib16","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa1014656","article-title":"Randomized trial of oral teriflunomide for relapsing multiple sclerosis","volume":"365","author":"O'Connor","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.clineuro.2024.108552_bib17","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1007\/s13311-017-0571-6","article-title":"Evolution of patient-reported outcomes and their role in multiple sclerosis clinical trials","volume":"14","author":"Nowinski","year":"2017","journal-title":"Neurotherapeutics"},{"issue":"3","key":"10.1016\/j.clineuro.2024.108552_bib18","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s40120-022-00384-2","article-title":"Real-world assessment of quality of life in patients with relapsing remitting multiple sclerosis treated with teriflunomide for two years: patient-reported outcomes from the AURELIO study in Greece","volume":"11","author":"Dardiotis","year":"2022","journal-title":"Neurol. Ther."},{"issue":"2","key":"10.1016\/j.clineuro.2024.108552_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/bmjno-2022-000315","article-title":"Treatment satisfaction in patients with relapsing-remitting multiple sclerosis initiated on teriflunomide in routine clinical practice: Australian observational data","volume":"4","author":"Hardy","year":"2022","journal-title":"BMJ Neurol. Open"},{"issue":"10","key":"10.1016\/j.clineuro.2024.108552_bib20","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1212\/WNL.0000000000002441","article-title":"Long-term safety and efficacy of teriflunomide: nine-year follow-up of the randomized TEMSO study","volume":"86","author":"O'Connor","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.clineuro.2024.108552_bib21","doi-asserted-by":"crossref","DOI":"10.1177\/11795735211028781","article-title":"Efficacy and safety of teriflunomide in multiple sclerosis across age groups: analysis from pooled pivotal and real-world studies","volume":"13","author":"Oh","year":"2021","journal-title":"J. Cent. Nerv. Syst. Dis."},{"key":"10.1016\/j.clineuro.2024.108552_bib22","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211005588","article-title":"Teriflunomide in relapsing-remitting multiple sclerosis: outcomes by age and pre-treatment status","volume":"14","author":"Kallmann","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.clineuro.2024.108552_bib23","first-page":"1","article-title":"Efficacy and safety of teriflunomide versus dimethyl fumarate for treating relapsing-remitting multiple sclerosis: a meta-analysis","volume":"16","author":"Masudo","year":"2021","journal-title":"Appl. Ther."},{"issue":"6","key":"10.1016\/j.clineuro.2024.108552_bib24","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/ane.13301","article-title":"Medication adherence\/persistence among patients with active multiple sclerosis in Finland","volume":"142","author":"Lahdenper\u00e4","year":"2020","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.clineuro.2024.108552_bib25","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2147\/PPA.S61651","article-title":"Teriflunomide for the treatment of relapsing\u2013remitting multiple sclerosis: patient preference and adherence","author":"Bayas","year":"2015","journal-title":"Patient Prefer. Adherence"}],"container-title":["Clinical Neurology and Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846724004396?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846724004396?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T21:07:14Z","timestamp":1730322434000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0303846724004396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":25,"alternative-id":["S0303846724004396"],"URL":"https:\/\/doi.org\/10.1016\/j.clineuro.2024.108552","relation":{},"ISSN":["0303-8467"],"issn-type":[{"type":"print","value":"0303-8467"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The patient-reported outcomes for the new brand-generic teriflunomide in relapsing-remitting multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Clinical Neurology and Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clineuro.2024.108552","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108552"}}